From Name:
From Email:
To Name:
To Email:

Optional Message:


PARP inhibitor improves outcomes in ovarian cancer

from Medscape Medical News

The experimental agent olaparib (AstraZeneca) might have a role to play in ovarian cancer. Results from a phase 2 trial have shown that it significantly prolonged progression-free survival in patients with platinum-sensitive relapsed serous ovarian cancer. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063